# The Effects of Empagliflozin on Arterial Wall Characteristics

> **NCT03639545** · PHASE4 · UNKNOWN · sponsor: **University Medical Centre Ljubljana** · enrollment: 120 (estimated)

## Conditions studied

- Vascular Stiffness
- Hypoglycemic Agents
- Diabetes Complications
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Empagliflozin 25mg
- **DRUG:** Metformin
- **DRUG:** Empagliflozin/Metformin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03639545
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2018-12-30
- **Final completion:** 2019-01-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639545, "The Effects of Empagliflozin on Arterial Wall Characteristics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03639545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*